🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

22 results for “Reata” Clear

  1. PF-06651600 Induction Dose

    Pfizer

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  2. PLACEBO FOR PF-06651600-15 CAPSULE, 100 MG, Ritlecitinib Tosilate, PLACEBO FOR PF-06651600-15 CAPSULE, 50 MG, Ritlecitinib tosilate

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  3. Placebo to match ritlecitinib 50 mg, Ritlecitinib tosilate, Ritlecitinib, Placebo to match ritlecitinib 30 mg

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  4. Ritlecitinib tosilate, Placebo to match ritlecitinib 50 mg, Ritlecitinib, Placebo to match ritlecitinib 30 mg

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  5. Ritlecitinib tosilate, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  6. Targretin Gel 1%

    LIGAND PHARMACEUTICALS INC

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  7. Upadacitinib Placebo, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Alopecia Areata

    phase 3 small molecule active

    1 trial

  8. ATI 502 0.46% Topical Solution

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  9. ATI-50002

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule completed

    1 trial

  10. ATI-50002 high dose

    Aclaris Therapeutics

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  11. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Alopecia areata

    phase 2 small molecule active

    1 trial

  12. CANNABIDIOL, DRONABINOL

    Disc Medicine

    Patients with untreatable hepatocellulare carcinoma

    phase 2 small molecule active

    1 trial

  13. Deucravacitinib

    Bristol-Myers Squibb

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  14. Dupilumab

    Regeneron UK Limited

    Alopecia Areata

    phase 2 small molecule active

    2 trials

  15. NKTR-358, Placebo

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  16. Placebo for LAD603, LAD603

    Almirall, S.A.

    Alopecia areata

    phase 2 small molecule active

    1 trial

  17. Rezpegaldesleukin

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  18. Stem Cell Educator

    The First People's Hospital of Lianyungang

    Alopecia Areata

    phase 2 other active

    1 trial

  19. A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS

    Lacuna Pharma Pty Ltd

    alopecia areata

    phase 1 other active

    1 trial

  20. A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

    Otsuka Beijing Research Institute

    Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata

    phase 1 other active

    1 trial

  21. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  22. FB102

    Forteo

    Alopecia Areata

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources